CARLSBAD, Calif.--(BUSINESS WIRE)--At the 36th annual European Congress of Pathology in Florence, Italy, Thermo Fisher Scientific, the world leader serving science, announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.

加利福尼亚州卡尔斯巴德（商业新闻短讯）--在意大利佛罗伦萨举行的第36届欧洲病理学年会上，世界领先的科学服务机构Thermo Fisher Scientific宣布了Oncomine临床研究基金的最新获得者，旨在支持新兴的肿瘤学分子谱研究，并帮助精准医学的未来民主化。

Now in its fourth year, the grant recognizes research from Tata Memorial Centre in India; Leiden University Center in The Netherlands; Western University in Canada; and Fred Hutch Cancer Center in the U.S..

该赠款现已进入第四年，用于表彰印度塔塔纪念中心的研究；荷兰莱顿大学中心；加拿大西部大学；和美国弗雷德·哈奇癌症中心。。

Since its introduction in 2020, the Oncomine Clinical Research Grant program has awarded reagents and general funding for 26 unique research projects conducted by independent clinical research teams. This research spans across 16 countries and five continents, encompassing research in solid-tumors, pediatric oncology, hemato-oncology, immune-oncology and liquid biopsy, all of which help enhance the understanding of potential new applications for accessible and rapid next-generation sequencing (NGS)..

自2020年推出以来，Oncomine临床研究资助计划已为独立临床研究团队进行的26个独特研究项目授予试剂和普通资金。这项研究跨越16个国家和五大洲，包括实体瘤，儿科肿瘤学，血液肿瘤学，免疫肿瘤学和液体活检的研究，所有这些都有助于增强对可访问和快速下一代测序（NGS）潜在新应用的理解。。

“This year, we saw the highest number of Oncomine Clinical Research Grant submissions since the program began in 2020. It’s a clear indication of the industry-wide push to accelerate research that explores the impacts of genomic discovery,” said Jose Luis Costa, Ph.D., global director, scientific affairs, clinical next-generation sequencing and oncology, Thermo Fisher Scientific.

。Thermo Fisher scientific科学事务、临床下一代测序和肿瘤学全球总监Jose Luis Costa博士说：“这清楚地表明，全行业都在努力加速研究，探索基因组发现的影响。”。

'As we continue to be inspired by the achievements and discoveries of the previous awardees, doubling down on supporting the next generation of clinical researchers who will further contribute to democratizing access to NGS technology is our key priority.'.

“随着我们继续受到先前获奖者的成就和发现的启发，加倍支持下一代临床研究人员，他们将进一步为NGS技术的民主化做出贡献，这是我们的关键优先事项。”。

Global Footprint of Oncomine Clinical Research Grant Expands

Oncomine临床研究基金的全球足迹扩大

Based on the last call for proposals in Spring 2024, four projects identified below were recognized at the European Congress of Pathology – including the first projects to be awarded this grant in India and Netherlands:

根据2024年春季的最后一次提案征集，欧洲病理学大会认可了以下四个项目，包括印度和荷兰首批获得该赠款的项目：

Professor Nikhil Patkar, Tata Memorial Centre, India – “Applicability of Measurable Residual Disease Testing in Acute Lymphoblastic Leukemia by Next Generation Sequencing.”

印度塔塔纪念中心的Nikhil Patkar教授：“通过下一代测序，可测量的残留疾病检测在急性淋巴细胞白血病中的适用性。”

This research project seeks to explore the detection of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia by using a highly sensitive immune repertoire assay leveraging the Oncomine platform. The overarching goal is to surpass traditional methods and assess future standards for accurate and reproducible MRD monitoring and risk assessment.

该研究项目旨在通过使用利用Oncomine平台的高灵敏度免疫库测定来探索小儿急性淋巴细胞白血病中微小残留病（MRD）的检测。总体目标是超越传统方法，评估未来准确和可重复的MRD监测和风险评估标准。

Dr. Dina Ruano, Leiden University Medical Center, Netherlands – “Exploring Homologous Recombination Deficiency Beyond Ovarian Cancer: Impact of DNA Quality on Outcomes.”

荷兰莱顿大学医学中心Dina Ruano博士：“探索卵巢癌以外的同源重组缺陷：DNA质量对结果的影响。”

This research project seeks to investigate precise genomic instability thresholds for homologous recombination deficiency in breast and prostate cancers using the OCA plus panel, while also exploring the potential of shallow whole-genome sequencing to assess HRD in low-quality samples, ultimately aiming to identify future robust and reliable methods for HRD detection across diverse cancer types..

该研究项目旨在使用OCA plus面板研究乳腺癌和前列腺癌同源重组缺陷的精确基因组不稳定性阈值，同时探索浅层全基因组测序评估低质量样本中HRD的潜力，最终旨在确定未来稳健可靠的方法，用于检测不同癌症类型的HRD。。

Professor Emilie Lalonde, London Health Sciences Center, Western University, Canada – 'Segmental CNV detection in FFPE Specimens with the Oncomine Comprehensive Assay v3: Combined SNV and CNV detection for future diagnostics.'

加拿大西部大学伦敦健康科学中心的Emilie Lalonde教授-“使用Oncomine综合分析v3在FFPE标本中进行节段性CNV检测：结合SNV和CNV检测以进行未来诊断。”

This research project aims to develop a novel segmental CNV detection algorithm using Oncomine generated data, with the potential to significantly enhance the diagnostic accuracy for brain tumors and melanocytic lesions by integrating CNV analysis with existing SNV and indel detection, paving the way for broader clinical applications across other cancer types..

该研究项目旨在开发一种使用Oncomine生成数据的新型节段性CNV检测算法，通过将CNV分析与现有SNV和indel检测相结合，有可能显着提高脑肿瘤和黑素细胞病变的诊断准确性，为其他癌症类型的更广泛临床应用铺平道路。。

Professor Cecilia CS Young, Fred Hutch Cancer Center, United States of America – 'Advancing Molecular Diagnosis with TCR Convergence and Global Oncology Efforts.”

美国弗雷德·哈奇癌症中心的Cecilia CS Young教授——“通过TCR融合和全球肿瘤学努力推进分子诊断。”

This research project aims to revolutionize cancer care in low- and middle-income countries by expanding their access to precision medicine through validated molecular assays on diverse sample types, including dried blood spots, while also pioneering the use of T-cell sequencing to predict immunotherapy responses, potentially transforming treatment strategies for cancers with complex immune signatures..

这项研究项目旨在通过对包括干血斑在内的多种样本类型进行有效的分子检测，扩大中低收入国家获得精准医学的机会，从而彻底改变中低收入国家的癌症护理，同时还开创了使用T细胞测序预测免疫治疗反应的先河，可能会改变具有复杂免疫特征的癌症的治疗策略。。

The next call for research proposals is now open through September 30, 2024. For more information, please visit www.oncomine.com/grants.

下一次征集研究提案的时间现在是2024年9月30日。有关更多信息，请访问www.oncomine.com/grants。

About Thermo Fisher Scientific

关于Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.

Thermo Fisher Scientific Inc.是服务科学领域的全球领导者，年收入超过400亿美元。我们的使命是让我们的客户使世界更健康、更清洁、更安全。无论我们的客户是在加速生命科学研究，解决复杂的分析挑战，提高实验室的生产力，通过诊断改善患者健康，还是在开发和制造改变生命的疗法，我们都会为他们提供支持。

Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com..

我们的全球团队通过我们的行业领先品牌，包括Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab services、Patheon和PPD，提供无与伦比的创新技术、购买便利和制药服务组合。有关更多信息，请访问www.thermofisher.com。。